These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
612 related articles for article (PubMed ID: 26746341)
21. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. Clausen A; Xu X; Bi X; Baudry M J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441 [TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of low fat-protein diet in the P301L mouse model of tauopathy. Buccarello L; Grignaschi G; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T Neuroscience; 2017 Jun; 354():208-220. PubMed ID: 28456717 [TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy. Crespo-Biel N; Theunis C; Borghgraef P; Lechat B; Devijver H; Maurin H; Van Leuven F Neurobiol Dis; 2014 Jul; 67():119-32. PubMed ID: 24704314 [TBL] [Abstract][Full Text] [Related]
24. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295 [TBL] [Abstract][Full Text] [Related]
25. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Vagnozzi AN; Giannopoulos PF; Praticò D Transl Psychiatry; 2017 Dec; 7(12):1288. PubMed ID: 29249809 [TBL] [Abstract][Full Text] [Related]
26. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130 [TBL] [Abstract][Full Text] [Related]
27. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. Seino Y; Kawarabayashi T; Wakasaya Y; Watanabe M; Takamura A; Yamamoto-Watanabe Y; Kurata T; Abe K; Ikeda M; Westaway D; Murakami T; Hyslop PS; Matsubara E; Shoji M J Neurosci Res; 2010 Dec; 88(16):3547-54. PubMed ID: 20936700 [TBL] [Abstract][Full Text] [Related]
28. Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy. Sun XY; Dong QX; Zhu J; Sun X; Zhang LF; Qiu M; Yu XL; Liu RT Curr Alzheimer Res; 2019; 16(8):710-722. PubMed ID: 31368873 [TBL] [Abstract][Full Text] [Related]
29. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. Ma DL; Chen FQ; Xu WJ; Yue WZ; Yuan G; Yang Y J Neurochem; 2015 Oct; 135(2):301-8. PubMed ID: 26183127 [TBL] [Abstract][Full Text] [Related]
30. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. Knudsen LB; Secher A; Hecksher-Sørensen J; Pyke C J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):56-63. PubMed ID: 27186357 [TBL] [Abstract][Full Text] [Related]
31. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635 [TBL] [Abstract][Full Text] [Related]
33. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy. Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476 [TBL] [Abstract][Full Text] [Related]
34. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087 [TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro. An FM; Chen S; Xu Z; Yin L; Wang Y; Liu AR; Yao WB; Gao XD Neuroscience; 2015 Aug; 300():75-84. PubMed ID: 25987199 [TBL] [Abstract][Full Text] [Related]
37. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810 [TBL] [Abstract][Full Text] [Related]
38. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Giannopoulos PF; Chu J; Sperow M; Li JG; Yu WH; Kirby LG; Abood M; Praticò D Biol Psychiatry; 2015 Nov; 78(10):693-701. PubMed ID: 25802082 [TBL] [Abstract][Full Text] [Related]
39. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy. Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099 [TBL] [Abstract][Full Text] [Related]
40. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice. Peng Y; Hu Y; Xu S; Li P; Li J; Lu L; Yang H; Feng N; Wang L; Wang X J Alzheimers Dis; 2012; 29(2):379-91. PubMed ID: 22233765 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]